0.0004EUR+100.00%Mkt Cap: 190 EURP/E: —Last update: 2026-06-01
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune disea…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap190 EUR
Enterprise Value132.25K EUR
Revenue (TTM)199.27K EUR
Gross Profit42.42K EUR
Net Income (TTM)-32.91M EUR
Revenue/Share0.4180 EUR
Last Price0.0004 EUR
Fiscal Year EndDec 2024
MR QuarterJun 2025
Employees16
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR00140077X1
Valuation
P/E (Trailing)—
P/E (Forward)0.00
PEG—
EV/EBITDA-0.02
EV/Revenue0.66
P/S0.00
P/B0.00
EPS (TTM)-221.36
EPS (Forward)0.10
52W Range
0.00020% of range4.200
52W High4.200 EUR
52W Low0.0002 EUR
Profitability
Gross Margin11.58%
Oper. Margin-1683.64%
EBITDA Margin0.00%
Profit Margin-8984.51%
ROE-182.23%
ROA-149.13%
Growth
Revenue Growth-59.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.60M EUR
CapEx (TTM)79.71K EUR
FCF Margin-1918.64%
FCF Yield-2012221.58%
Net Debt132.15K EUR
Net Debt/EBITDA-0.02
Balance Sheet
Debt/Equity0.01
Current Ratio0.67
Quick Ratio0.65
Book Value/Sh39.63 EUR
Cash/Share0.0810 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10000
Split DateJun 23, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.476.63K
Float—
Insiders0.00%
Institutions0.00%
Technical
SMA 500.0004 (+5.3%)
SMA 2000.0860 (-99.5%)
Beta42.06
S&P 52W Chg27.94%
Avg Vol (30d)55.85M
Avg Vol (10d)33.03M
Technical Indicators
RSI (14)39.0
MACD-0.0001
MACD Signal-0.0001
MACD Hist.+0.0000
BB Upper0.0003 EUR
BB Middle0.0002 EUR
BB Lower0.0001 EUR
BB Width85.18%
ATR (14)0.0002 EUR
Vol Ratio (20d)0.43x